The Drugs Controller General of India (DCGI) has approved the market authorization of India’s first quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Serum Institute of India (SII) will produce this vaccine. CEO of The Serum Institute of India Adar Poonawalla tweeted the information. For the first time, an inexpensive and widely available HPV vaccination made in India will be available to treat cervical cancer in female patients. Later this year, SII hopes to launch it, and we are grateful to the DCGI, MoHFW INDIA, for their approval.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV. The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15. After the vaccine’s phase 3 data were deemed to be satisfactory, suggestions were made.
Important Takeaways For All Competitive Exams:
India's cities are often known not just by their original names but also by unique…
On May 5th, the world unites to celebrate the Portuguese language, a linguistic treasure that…
In a groundbreaking endeavor, China has launched the Chang'e-6 probe on an ambitious mission to…
Frank Shrontz, who led Boeing as its Chief Executive Officer for a decade from 1986…
Lando Norris of McLaren clinched his first-ever Grand Prix victory in a pulsating showdown at…
India, renowned for its rich cultural heritage and diverse landscapes, also boasts a thriving tea…